

# Cheol-Kyu Park

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1773420/cheol-kyu-park-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

338  
citations

12  
h-index

16  
g-index

52  
ext. papers

442  
ext. citations

3.4  
avg, IF

3.19  
L-index

#	Paper	IF	Citations
44	A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 777-787	5.2	26
43	Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 800-4	3.2	21
42	Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 661-9	5.2	19
41	Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e775-e781	4.9	17
40	Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 2530-2537	2.6	16
39	Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 856-864	3.2	16
38	Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e289-e296	4.9	15
37	Development of antisynthetase syndrome in a patient with rheumatoid arthritis. <i>Rheumatology International</i> , <b>2011</b> , 31, 529-32	3.6	15
36	Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. <i>Immune Network</i> , <b>2020</b> , 20, e27	6.1	15
35	Inverse association of peripheral blood CD4(+) invariant natural killer T cells with atopy in human asthma. <i>Human Immunology</i> , <b>2010</b> , 71, 186-91	2.3	14
34	Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 507-514	4.4	13
33	Clinical factors associated with weaning failure in patients requiring prolonged mechanical ventilation. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 143-150	2.6	12
32	Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease. <i>Tuberculosis and Respiratory Diseases</i> , <b>2014</b> , 77, 161-6	3.2	12
31	Microbiological Characteristics and Predictive Factors for Mortality in Pleural Infection: A Single-Center Cohort Study in Korea. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161280	3.7	12
30	Pulmonary sclerosing pneumocytoma mimicking lung cancer: Case report and review of the literature. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 508-11	3.2	12
29	Predictors of Default from Treatment for Tuberculosis: a Single Center Case-Control Study in Korea. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 254-60	4.7	11
28	Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. <i>BMC Cancer</i> , <b>2016</b> , 16, 690	4.8	11

27	Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2045-2049	3.2	7
26	Acute respiratory distress syndrome and chemical burns after exposure to chlorine-containing bleach: a case report. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, E17-E20	2.6	7
25	Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e7	4.7	7
24	Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression. <i>Tuberculosis and Respiratory Diseases</i> , <b>2019</b> , 82, 227-233	3.2	6
23	Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1585-1590	4.4	5
22	Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 639-647	3.2	5
21	Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 942-949	3.2	4
20	A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer. <i>Oncology</i> , <b>2018</b> , 94, 373-382	3.6	4
19	Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 408-414	3.2	4
18	Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature. <i>Open Medicine (Poland)</i> , <b>2016</b> , 11, 174-177	2.2	4
17	Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e342	4.7	4
16	Review of Sarcoidosis in a Province of South Korea from 1996 to 2014. <i>Tuberculosis and Respiratory Diseases</i> , <b>2017</b> , 80, 291-295	3.2	3
15	Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5809-5822	4.8	3
14	Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 1914-1921	4.7	2
13	Different characteristics associated with intensive care unit transfer from the medical ward between patients with acute exacerbations of chronic obstructive pulmonary disease with and without pneumonia. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 1121-31	2.6	2
12	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 525-9	3.2	1
11	Risk factors for primary lung cancer among never-smoking women in South Korea: a retrospective nationwide population-based cohort study. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 692-702	2.5	1
10	Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1598-1604	3.2	1

9	Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 444-452	3.2	1
8	A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. <i>Cancer Research and Treatment</i> , <b>2021</b> , 53, 93-103	5.2	1
7	Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1264-1268	3.2	1
6	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 224-6	3.2	0
5	Potentially fatal complications of systemic air embolism after computed tomography-guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3401-3406	3.2	0
4	First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.. <i>Anticancer Research</i> , <b>2022</b> , 42, 1615-1622	2.3	0
3	Superior vena cava syndrome with extensive collateral vessels. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2322	3.2	
2	Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients. <i>Tuberculosis and Respiratory Diseases</i> , <b>2021</b> , 84, 105-114	3.2	
1	Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9072-9072	2.2	